Wild-type p53 activates transcription in vitro
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The p53 protein is an important determinant in human cancer and regulates the growth of cells in culture. It is known to be a sequence-specific DNA-binding protein with a powerful activation domain, but it has not been established whether it regulates transcription directly. Here we show that intact purified wild-type human and murine p53 proteins strongly activate transcription in vitro. This activation depends on the ability of p53 to bind to a template bearing a p53-binding sequence. By contrast, tumour-derived mutant p53 proteins cannot activate transcription from the template at all, and when complexed to wild-type p53, these mutants block transcriptional activation by the wild-type protein. Moreover, the simian virus 40 large T antigen inhibits wild-type p53 from activating transcription. Our results support a model in which p53 directly activates transcription but this activity can be inhibited by mutant p53 and SV40 large T antigen through interaction with wild-type p53.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The tumor-suppressor protein, p53, plays a central role in the cellular response to UV-induced DNA damage/repair (13).”
From Melanocyte-stimulating hormone directly enhances UV-Induced DNA repair in keratinocytes by a xeroderma pigmentosum group A-dependent mechanism (2010) · cites this paper as [13]
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
How eukaryotic transcriptional activators work
Ptashne, M. (1988) · Nature · doi:10.1038/335683a0 · Cited by 1,825
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
p53: oncogene or anti-oncogene?
Lane, D. P., & Benchimol, S. (1990) · Genes & Development · doi:10.1101/gad.4.1.1 · Cited by 795
Presence of a Potent Transcription Activating Sequence in the p53 Protein
Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790
Gannon, J. V., Greaves, R., Iggo, R., & Lane, D. P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08279.x · Cited by 688
Transcriptional Activation by Wild-Type but Not Transforming Mutants of the p53 Anti-Oncogene
Raycroft, L., Wu, H., & Lozano, G. (1990) · Science · doi:10.1126/science.2144364 · Cited by 619
Research works printed but not linked: 7
- O'Rourke, R. W. et al. Oncogene 5, 1829–1832 (1990).
- Zhu, H., Roy, A. L., Roeder, R. G. & Prywes, R. New Biologist 3, 455–464 (1991).
- Kern, S. E. et al. Oncogene 6, 131–136 (1991).
- Fried, M. & Prives, C. Cancer Cells 4, 1–16 (1986).
- Soussi, T., Caron de Fromentel, C. & May, P. Oncogene 5, 945–952 (1990).
- Murakami, Y., Asano, M., Satake, M. & Ito, Y. Oncogene 5, 5–14 (1990).
- Zambetti, G. P. et al. Genes Dev. (in the press).
Cited by
Items 201–300 of 578
Cul7/p185/p193 Binding to Simian Virus 40 Large T Antigen Has a Role in Cellular Transformation
Ali, S. H., Kasper, J. S., Arai, T., & DeCaprio, J. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.2749-2757.2004 · Cited by 94
“p53’s ability to serve as a transcription factor (5, 16, 57).”
BackgroundGerm cell tumors of the testis overexpress wild-type p53.
Guillou, L., Estreicher, A., Chaubert, P., HURLIMANN, J., Kurt, A.-M., Metthez, G., Iggo, R. D., Gray, A., Jichlinski, P., Leisinger, H., et al. (1996) · PubMed Central · Cited by 82
Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes.
Buckbinder, L., Talbott, R., Seizinger, B. R., & Kley, N. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.22.10640 · Cited by 82
Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53.
Yap, N., Yu, C. L., & Cheng, S. Y. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4273 · Cited by 82
GERMLINE p53 MUTATIONS AND HERITABLE CANCER
Malkin, D. (1994) · Annual Review of Genetics · doi:10.1146/annurev.ge.28.120194.002303 · Cited by 59
p300 family members associate with the carboxyl terminus of simian virus 40 large tumor antigen
Lill, N. L., Tevethia, M. J., Eckner, R., Livingston, D. M., & Modjtahedi, N. (1997) · Journal of Virology · doi:10.1128/jvi.71.1.129-137.1997 · Cited by 93
The expression of p73 is increased in lung cancer, independent of p53 gene alteration
Tokuchi, Y., Hashimoto, T., Kobayashi, Y., Hayashi, M., 西田, 一., Hayashi, S., Imai, K., Nakachi, K., Ishikawa, Y., Nakagawa, K., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690572 · Cited by 81
Ariyoshi, K., Kawauchi, S., Kaku, T., Nakano, H., & Tsuneyoshi, M. (2000) · Histopathology · doi:10.1046/j.1365-2559.2000.01015.x · Cited by 80
Induction of cell growth regulatory genes by p53.
Madden, S. L., Galella, E. A., Riley, D., Bertelsen, A. H., & Beaudry, G. A. (1996) · PubMed · Cited by 80
Tokumoto, Y. M., Tang, D. G., & RAFF, M. C. (2001) · The EMBO Journal · doi:10.1093/emboj/20.18.5261 · Cited by 86
Molecular defects in the pathogenesis of pituitary tumours
Levy, A., & Lightman, S. L. (2003) · Frontiers in Neuroendocrinology · doi:10.1016/s0091-3022(03)00012-8 · Cited by 86
p53 expression during normal tissue regeneration in response to acute cutaneous injury in swine.
Antoniades, H. N., Galanopoulos, T., Neville-Golden, J., Kiritsy, C. P., & Lynch, S. E. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117217 · Cited by 76
Negative regulation of transcription in eukaryotes
Clark, A. R., & Docherty, K. (1993) · Biochemical Journal · doi:10.1042/bj2960521 · Cited by 88
30 years and a long way into p53 research
Hainaut, P. L., & Wiman, K. G. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70198-6 · Cited by 89
Aberrant accumulation of p53 associates with Ki67 and mitotic count in benign skin lesions
SOINI, Y., Kamel, D., Pääkkö, P. K., Lehto, V.-P., Oikarinen, A., & Vähäkangas, K. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1994.tb08552.x · Cited by 83
Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma
Simon, B., Weinel, R. J., Höhne, M. W., Watz, J., Schmidt, J., Körtner, G., & Arnold, R. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90422-7 · Cited by 81
Farmer, G. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.21.4281 · Cited by 74
Quartin, R. S., Cole, C. N., Pipas, J. M., & Levine, A. J. (1994) · Journal of Virology · doi:10.1128/jvi.68.3.1334-1341.1994 · Cited by 73
“When T antigen binds to p53, it inactivates its ability to bind to DNA and act as a transcription factor at a p53-responsive element (14, 39, 49), just as mutations in the p53 gene block this same function (14, 26, 62).”
BackgroundTseng, P., Tai, M., Huang, C., Wang, C., Lin, J., Hung, C., Chen, C., Wang, J., Lu, S., Lee, C., et al. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.21109 · Cited by 72
p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma.
Hirvikoski, P. P., Kumpulainen, E., Virtaniemi, J. A., Johansson, R. T., Haapasalo, H. K., Marin, S., Halonen, P., Helin, H. O., Raitiola, H. S., Pukander, J., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.9.3111 · Cited by 71
Differential regulation of p21 by p53 and Rb in cellular response to oxidative stress
Yin, Y., Solomon, G., Deng, C., & Barrett, J. C. (1999) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199901)24:1<15::aid-mc3>3.0.co;2-y · Cited by 71
Kulesz-Martin, M. F., Lisafeld, B., Huang, H., Kisiel, N. D., & Lee, L. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1698 · Cited by 71
FinO is an RNA chaperone that facilitates sense–antisense RNA interactions
Arthur, D. C., Ghetu, A. F., Gubbins, M. J., Edwards, R. A., Frost, L. S., & Glover, J. N. M. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg607 · Cited by 73
Gotoh, A., Kao, C. H., Ko, S.-C., Hamada, K., Liu, T.-J., & Chung, L. W. K. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)64574-9 · Cited by 77
Ruiz‐Lozano, P., Hixon, M. L., Wagner, M. W., Flores, A. I., Ikawa, S., Baldwin, A. S., Chien, K. R., & Gualberto, A. (1999) · PubMed · Cited by 77
Focal adhesion kinase and p53 signal transduction pathways in cancer
Vita, M. G. (2010) · Frontiers in bioscience · doi:10.2741/3653 · Cited by 71
Human tumor suppressor p53 and DNA viruses
Collot‐Teixeira, S., Bass, J., Denis, F., & Ranger‐Rogez, S. (2004) · Reviews in Medical Virology · doi:10.1002/rmv.431 · Cited by 69
“In response to damaged DNA, nucleotide depletion, hypoxia, oncogene expression, metabolic changes or viral infections, p53 accumulates in the nucleus and is activated as a transcription factor [13].”
Molecular Dynamics Simulations of p53 DNA-Binding Domain
Lu, Q., Tan, Y.-H., & Luo, R. (2007) · The Journal of Physical Chemistry B · doi:10.1021/jp0742261 · Cited by 68
Chae, H., Choi, T.-S., Kim, B.-M., Jung, J. H., Bang, Y., & Shin, D. Y. (2005) · Oncogene · doi:10.1038/sj.onc.1208640 · Cited by 67
“Functional analyses of p53 protein have revealed that it is a transcription factor with sequence-specific DNAbinding activity (Farmer et al., 1992; Kern et al., 1992; Zambetti et al., 1992), and that it activates the transcription of several downstream target genes, including p21, an inhibitor of…”
BackgroundShaulian, E., Zauberman, A., Milner, J., Davies, E. A., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05940.x · Cited by 78
The p53 tumour suppressor gene: a mediator of a G1 growth arrest and of apoptosis
Yonish-Rouach, E. (1996) · Cellular and Molecular Life Sciences · doi:10.1007/bf01920109 · Cited by 73
Irradiation Induces WAF1 Expression through a p53-independent Pathway in KG-1 Cells
Akashi, M., Hachiya, M., Osawa, Y., Spirin, K. S., Suzuki, G., & Koeffler, H. P. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.32.19181 · Cited by 73
Dong, L., Wen, J., Pier, E., Zhang, X., Zhang, B., Dong, F., Ziegler, N., Mysz, M., Armenta, R., & Cui, R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4596 · Cited by 65
“The tumor suppressor protein p53 plays a central role in the cellular response to UV-induced DNA damage/ repair (13).”
BackgroundLiang, J., Li, G., Liao, J., Huang, Z., Wen, J., Wang, Y., Chen, Z., Cai, G., Xu, W., Ding, Z., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00929-w · Cited by 67
“It can be activated in response to DNA damage or the aberrant activation of oncogenes leading to induction of a wide variety of cellular processes including cell cycle arrest, apoptosis and senescence [16, 17].”
BackgroundA functional screen for germ line p53 mutations based on transcriptional activation.
Frébourg, T., Barbier, N., Kassel, J., Ng, Y. S., Beer‐Romero, P., & Friend, S. H. (1992) · PubMed · Cited by 67
Evans, M. K., Taffe, B. G., Harris, C. C., & Bohr, V. A. (1993) · PubMed · Cited by 68
Nitric Oxide-Mediated Inhibition of Hdm2−p53 Binding
Schonhoff, C. M., Daou, M.-C., Jones, S. N., Schiffer, C. A., & Ross, A. H. (2002) · Biochemistry · doi:10.1021/bi026262q · Cited by 63
Induction of genetic instability by gain-of-function p53 cancer mutants
Xu, Y. (2008) · Oncogene · doi:10.1038/sj.onc.1211023 · Cited by 69
“In this context, studies in cancer cell lines have shown that the common p53 cancer mutants cannot bind to p53 target promoters and transactivate target gene expression (el-Deiry et al., 1992; Farmer et al., 1992; Kern et al., 1992; Scharer and Iggo, 1992).”
BackgroundApoptosis in the Pathogenesis of Cutaneous Lupus Erythematosus
Chung, J. H., Kwon, O., Eun, H. C., Youn, J. I., Song, Y. W., Kim, J. G., & Cho, K. H. (1998) · American Journal of Dermatopathology · doi:10.1097/00000372-199806000-00002 · Cited by 62
Dessì, S., Batetta, B., Pulisci, D., Spano, O., Anchisi, C., Tessitore, L., Costelli, P., Baccino, F. M., Aroasio, E., & Pani, P. (1994) · Cancer · doi:10.1002/1097-0142(19940115)73:2<253::aid-cncr2820730204>3.0.co;2-f · Cited by 139
Mechanisms of Transcriptional Regulation of Cellular Genes by SV40 Large T- and Small T-Antigens
Moens, U. L., Seternes, O. M., Johansen, B., & Rekvig, O. P. (1997) · Virus Genes · doi:10.1023/a:1007962908248 · Cited by 68
Ko, J., Lee, Y. H., Hwang, S. Y., Lee, Y. S., Shin, S. M., Hwang, J. H., Kim, J. S., Kim, Y. W., Jang, S.-W., Ryoo, Z. Y., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206624 · Cited by 62
“The p53 tumor suppressor gene product is a shortlived transcription factor (Farmer et al., 1992) of target genes that regulates cell cycle check points (El-Deiry et al., 1993).”
BackgroundWeidman, M. K., Yalamanchili, P., Ng, B., Tsai, W., & Dasgupta, A. (2001) · Virology · doi:10.1006/viro.2001.1215 · Cited by 61
Teodoro, J. G., Halliday, T., Whalen, S. G., Takayesu, D., Graham, F. L., & Branton, P. E. (1994) · Journal of Virology · doi:10.1128/jvi.68.2.776-786.1994 · Cited by 61
Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells
Soddu, S., Blandino, G., Citro, G., Scardigli, R., Piaggio, G., Ferber, A., Calabretta, B., & Sacchi, A. (1994) · Blood · doi:10.1182/blood.v83.8.2230.2230 · Cited by 61
V(D)J Recombination and Double-Strand Break Repair
Weaver, D. T. (1995) · Advances in immunology · doi:10.1016/s0065-2776(08)60619-7 · Cited by 65
Dietz, S., Rother, K., Bamberger, C., Schmale, H., Mössner, J., & Engeland, K. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03093-4 · Cited by 64
Thukral, S. K., Blain, G. C., Chang, K. K., & Fields, S. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.12.8315 · Cited by 60
Winter, M., Milne, D., Dias, S., Kulikov, R., Knippschild, U., Blattner, C., & Meek, D. (2004) · Biochemistry · doi:10.1021/bi0489255 · Cited by 60
Heinlein, C., Krepulat, F., Löhler, J., Speidel, D., Deppert, W., & Tolstonog, G. V. (2008) · International Journal of Cancer · doi:10.1002/ijc.23317 · Cited by 59
“The model represents a p53 ‘‘loss of function’’ setting, as in MEC of induced WAP-T mice the SV40 T-Ag complexes and functionally compromises the endogenous wtp53.(12)”
BackgroundRedox modulation of p53: Mechanisms and functional significance
Kim, D., Kundu, J. K., & Surh, Y. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20709 · Cited by 62
“The central DNA-binding domain interacts with consensus p53 binding sequences located in the proximal promoter regions of target genes [23,24].”
BackgroundDNA damage, oncogenesis and the p53 tumour-suppressor gene
Lee, J. M., Abrahamson, J., & Bernstein, A. (1994) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(94)90267-4 · Cited by 64
Sabbatini, P., Han, J., Chiou, S., Nicholson, D. W., & White, E. P. (1997) · PubMed · Cited by 67
Regulation of p53-Dependent Apoptosis by E1A and E1B
White, E. (1995) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-79586-2_3 · Cited by 59
Brown, D. R., Deb, S., Muñoz, R. M., Subler, M. A., & Deb, S. P. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.11.6849 · Cited by 58
Lack ofp53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions
Papp, T., Jafari, M., & Schiffmann, D. (1996) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01213550 · Cited by 64
“In general, p53 has inhibitory effects on cell growth by acting as a transcriptional regulator for an unknown number of genes (Levine et al. 1991; Farmer et al. 1992 ).”
BackgroundPresence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma.
Soini, Y., Nuorva, K., Kamel, D., Pollanen, R., Vähäkangas, K., Lehto, V.-P., & Pääkkö, P. K. (1996) · Thorax · doi:10.1136/thx.51.9.887 · Cited by 59
Eastham, J. A., Grafton, W. D., Martin, C. M., & Williams, B. J. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67320-x · Cited by 57
Haines, D. S. (1997) · Leukemia & Lymphoma · doi:10.3109/10428199709051772 · Cited by 57
A comprehensive study of p53 protein
Patil, M. R., & Bihari, A. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30331 · Cited by 64
“Numerous roles of p53 are related to the ability to function as a sequence‐specific transcription factor that affects multiple cellular processes, including the crucial role in tumor elimination.(58) p53 accumulates in the nucleus as a reaction to different types of stress, links to certain locations in p53‐responding…”
BackgroundBromberg, J. S., DeBruyne, L. A., & Qin, L. (1998) · Advances in immunology · doi:10.1016/s0065-2776(08)60611-2 · Cited by 58
Marcellus, R. C., Teodoro, J. G., Charbonneau, R., Shore, G. C., & Branton, P. E. (1996) · PubMed · Cited by 55
Emamzadah, S., Tropia, L., & Halazonetis, T. D. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0351 · Cited by 55
CDKN2A-p53 mediated antitumor effect of Lupeol in head and neck cancer
Bhattacharyya, S., Sekar, V., Majumder, B., Mehrotra, D. G., Banerjee, S., Bhowmick, A. K., Alam, N., Mandal, G., Biswas, J., Majumder, P. K., et al. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0311-7 · Cited by 58
Kawasaki, M., Nakanishi, Y., Kuwano, K., Yatsunami, J., Takayama, K., & Hara, N. (1997) · PubMed · Cited by 55
Denison, S. H., Käfer, E., & May, G. S. (1993) · Genetics · doi:10.1093/genetics/134.4.1085 · Cited by 55
Woodworth, C. D., Wang, H., Simpson, S., Álvarez-Salas, L. M., & Notario, V. (1993) · PubMed · Cited by 62
p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus.
Puisieux, A., Ji, J., Guillot, C., Legros, Y., Soussi, T., Isselbacher, K. J., & Öztürk, M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1342 · Cited by 57
Analysis of a Protein-Binding Domain of p53
Ruppert, J. M., & Stillman, B. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.6.3811 · Cited by 54
Kawasaki, M., Nakanishi, Y., Kuwano, K., Takayama, K., Kiyohara, C., & Hara, N. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00067-7 · Cited by 53
The Tumor Suppressor p53 Can Both Stimulate and Inhibit Ultraviolet Light–induced Apoptosis
McKay, B. C., Chen, F., Perumalswami, C. R., Zhang, F., & Ljungman, M. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.8.2543 · Cited by 53
“Vol. 11, August 2000 2547 Overexpression of p53 is thought to transactivate hundreds of genes ( Farmer et al., 1992; Zambetti et al., 1992; Smith and Fornace, 1997).”
BackgroundZettler, C., Bridges, D. C. M., Zhou, X., & Rush, R. A. (1996) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19961201)46:5<581::aid-jnr7>3.0.co;2-f · Cited by 65
Benoît, V., Hellin, A., Huygen, S., GIELEN, J. E., Bours, V., & Merville, M.-P. (2000) · Oncogene · doi:10.1038/sj.onc.1203831 · Cited by 52
“The WT-activated p53 acts as a transcriptional factor and regulates the expression of target genes including p21(WAF1/CIP1), gadd45, bax or bcl2, which in turn control cell cycle checkpoints, DNA repair and apoptosis (Kern et al., 1991; Farmer et al., 1992; Miyashita et al., 1994).”
BackgroundWu, Y., Liu, Y., Lee, L., Miner, Z., & Kulesz-Martin, M. F. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06808.x · Cited by 62
Field, J. K., Zoumpourlis, V., Spandidos, D. A., & Jones, A. S. (1994) · PubMed · Cited by 63
Nahor, I., Abramovitch, S., Engeland, K., & Werner, H. (2005) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2005.07.005 · Cited by 42
“[39] G.”
BackgroundTransactivation of Prothymosin α and c-mycPromoters by Human Papillomavirus Type 16 E6 Protein
Kinoshita, T., Shirasawa, H., Shino, Y., Moriya, H., Desbarats, L., Eilers, M., & Simizu, B. (1997) · Virology · doi:10.1006/viro.1997.8536 · Cited by 54
p53: DNA damage, DNA repair, and apoptosis
Götz, C., & Montenarh, M. (1995) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/bfb0048265 · Cited by 53
Adenovirus Degradation of Cellular Proteins
Schreiner, S., Wimmer, P., & Dobner, T. (2012) · Future Microbiology · doi:10.2217/fmb.11.153 · Cited by 58
Metal and RNA Binding Properties of the hdm2 RING Finger Domain
Lai, Z., Freedman, D. A., Levine, A. J., & McLendon, G. L. (1998) · Biochemistry · doi:10.1021/bi980596r · Cited by 49
Discrimination of DNA Binding Sites by Mutant p53 Proteins
Thukral, S. K., Lu, Y., Blain, G. C., Harvey, T. S., & Jacobsen, V. L. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.9.5196 · Cited by 52
“TGCCT from AT to CG and from TA to GC, respectively, in both repeats.”
BackgroundInfluentialShi, Y.-Z., Hui, A.-M., Takayama, T., Li, X., Cui, X., & Makuuchi, M. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1310 · Cited by 50
“…and loss of function of p53 is caused not by gene mutation but also when p53 protein interacts with vir cellular oncoproteins (Sarnow et al, 1982; Farmer et al, 1992; and Berk, 1992; Steegenga et al, 1996; Somasundaram an Deiry, 1997), it is necessary to investigate p21WAF1/CIP1 and p53 at the…”
BackgroundThe dominating effect of mutant p53
Hann, B. C., & Lane, D. P. (1995) · Nature Genetics · doi:10.1038/ng0395-221 · Cited by 55
Tumor Suppressor p53 and Its Homologue p73α Affect Cell Migration
Sablina, A. A., Chumakov, P. M., & Kopnin, B. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300547200 · Cited by 49
Reversal of In Vitro p53 Squelching by both TFIIB and TFIID
Liu, X. E., & Berk, A. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.11.6474 · Cited by 48
“It functions as a typical sequence-specific transcriptional activator (8, 17) that binds as a tetramer (15) to four tandem, alternatively inverted copies of a 5-bp consensus sequence (4, 13).”
BackgroundDecreased expression of Bax is correlated with poor prognosis in oral and oropharyngeal carcinoma
Ito, T., Fujieda, S., Tsuzuki, H., Sunaga, H., Fan, G., Sugimoto, C., Fukuda, M., & Saitô, H. (1999) · Cancer Letters · doi:10.1016/s0304-3835(99)00055-5 · Cited by 48
Tumor-Suppressor genes in pancreatic cancer
Hruban, R. H., Offerhaus, G. J. A., Kern, S. E., Goggins, M., Wilentz, R. E., & Yeo, C. J. (1998) · Journal of Hepato-Biliary-Pancreatic Surgery · doi:10.1007/s005340050062 · Cited by 48
Reversal of the DNA-Binding-Induced Loop L1 Conformational Switch in an Engineered Human p53 Protein
Emamzadah, S., Tropia, L., Vincenti, I., Falquet, B., & Halazonetis, T. D. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.12.020 · Cited by 47
“The p53 protein contains two independently folding domains: a sequence-specific DNA binding domain at its center (also known as the core domain) and a homo-tetramerization domain towards the C-terminus [6-8].”
Backgroundp53 and MDM2 expression in odontogenic cysts and tumours
Carvalhais, J. N., Aguiar, M., de Araújo, V. C., de Araújo, N., & Gomez, R. S. (1999) · Oral Diseases · doi:10.1111/j.1601-0825.1999.tb00304.x · Cited by 55
Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor development
Aubrey, B. J., Janic, A., Chen, Y., Chang, C., Lieschke, E. C., Diepstraten, S. T., Kueh, A. J., Bernardini, J. P., Dewson, G., O'Reilly, L. A., et al. (2018) · Genes & Development · doi:10.1101/gad.314286.118 · Cited by 47
“…half-life of mutant TRP53 (Freed-Pastor and Prives 2012) and the formation of mixed tetramers with the wild-type TRP53 protein (Milner et al. 1991; Farmer et al. 1992; Sturzbecher et al. 1992; Jeffrey et al. 1995) that impair normal transcriptional control of wild-type TRP53 target genes (Willis…”
p53, proto-oncogene and rheumatoid arthritis
Sun, Y., & Cheung, H. S. (2002) · Seminars in Arthritis and Rheumatism · doi:10.1053/sarh.2002.31550 · Cited by 48
Watson, A. J. M. (1995) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1995.tb00376.x · Cited by 49
Lee, Y., Chen, Y., Chang, L., & Johnson, L. F. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3605 · Cited by 50
Tumor suppressor genes and their roles in breast cancer
Cox, L. A., Chen, G., & Lee, E. Y. H. P. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666203 · Cited by 54
“The acidic domain in the amino-terminal region of p53 has transactivation activity [84,85].”
BackgroundGolubovskaya, V., & Cance, W. G. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.06.003 · Cited by 51
“The p53 protein is a transcription factor that binds as a tetramer to the following DNA consensus sequence: 5’Pu-Pu-Pu-C-A/T-T/A-G-Py-Py-Py3’ (Pu-purine; Py-pyrimidine) in the promoters of the several genes, such as p21, Bax, Mdm-2, and PUMA and activates their transcription (2).”
BackgroundYook, J. I., & Kim, J. H. (1998) · Oral Oncology · doi:10.1016/s1368-8375(97)00091-2 · Cited by 53
HEPATOTOXICITY AND ABSORPTION OF EXTRAHEPATIC ACETALDEHYDE IN RATS
Matysiak‐Budnik, T., Jokelainen, K., Kärkkäinen, P., Mäkisalo, H., Ohisalo, J. J., & Salaspuro, M. P. (1996) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199604)178:4<469::aid-path510>3.0.co;2-9 · Cited by 39
Subler, M. A., Martin, D. W., & Deb, S. (1994) · Journal of Virology · doi:10.1128/jvi.68.1.103-110.1994 · Cited by 48
“Wild-type p53 (but not a mutant) activated a promoter with p53-binding sites both in vivo and in vitro (18, 25, 36, 93).”
BackgroundDembla, V., Somaiah, N., Barata, P. C., Hess, K. R., Fu, S., Jankú, F., Karp, D. D., Naing, A., Piha-Paul, S. A., Subbiah, V., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26075 · Cited by 43
“The p53 pathway is responsible for sequence-specific transcriptional activation (both in vivo and in vitro)[2, 3] and perturbations to this pathway are present during the development of most cancers [4].”
BackgroundBleomycin Sensitivity of Mice Expressing Dominant-Negative p53 in the Lung Epithelium
Ghosh, S., Mendoza, T. M., Ortiz, L. A., Hoyle, G. W., Fermin, C. D., Brody, A. R., Friedman, M. B., & Morris, G. F. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2109094 · Cited by 44
Metadata
- Authors
- Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., & Prives, C.
- Affiliations
- Columbia University (US)
- Venue
- Nature
- Published
- 1992-07
- Volume
- 358
- Issue
- 6381
- Pages
- 83-86
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2063158632
- Cited by
- 579
- References
- 29
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 8 · 2021: 5 · 2020: 8 · 2019: 3 · 2018: 4 · 2017: 1 · 2016: 4 · 2015: 1 · 2014: 6 · 2013: 5 · 2012: 7
- FWCI
- 38.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p53, transcriptional activation, wild-type p53, mutant p53, SV40 large T antigen, DNA-binding proteins, tumour suppressor, protein-protein interaction, transcriptional repression
- MeSH terms
- Animals, Antigens, Polyomavirus Transforming, DNA Mutational Analysis, DNA-Binding Proteins, Gene Expression Regulation, HeLa Cells, Humans, Neoplasm Proteins, Promoter Regions, Genetic, Structure-Activity Relationship, Transcription Factors, Transcription, Genetic, Tumor Suppressor Protein p53, Mice, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.